NO982815L - Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet - Google Patents

Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet

Info

Publication number
NO982815L
NO982815L NO982815A NO982815A NO982815L NO 982815 L NO982815 L NO 982815L NO 982815 A NO982815 A NO 982815A NO 982815 A NO982815 A NO 982815A NO 982815 L NO982815 L NO 982815L
Authority
NO
Norway
Prior art keywords
ultra
menstrual bleeding
less
low dose
oral contraceptives
Prior art date
Application number
NO982815A
Other languages
English (en)
Other versions
NO982815D0 (no
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982815(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of NO982815D0 publication Critical patent/NO982815D0/no
Publication of NO982815L publication Critical patent/NO982815L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO982815A 1997-06-23 1998-06-18 Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet NO982815L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/880,419 US5898032A (en) 1997-06-23 1997-06-23 Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
CA002256977A CA2256977C (en) 1997-06-23 1998-12-23 Methods of extended use oral contraception

Publications (2)

Publication Number Publication Date
NO982815D0 NO982815D0 (no) 1998-06-18
NO982815L true NO982815L (no) 1998-12-28

Family

ID=32043766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982815A NO982815L (no) 1997-06-23 1998-06-18 Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet

Country Status (10)

Country Link
US (2) US5898032A (no)
EP (1) EP0911029B1 (no)
JP (1) JPH1129481A (no)
AT (1) ATE216241T1 (no)
CA (1) CA2256977C (no)
DE (1) DE69804918T2 (no)
DK (1) DK0911029T3 (no)
ES (1) ES2175650T3 (no)
NO (1) NO982815L (no)
PT (1) PT911029E (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP1148884A4 (en) * 1998-11-12 2003-06-11 Warner Chilcott Lab Ireland Lt Contraceptive with graded progestin
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
DK1406633T3 (da) 2001-06-18 2011-10-31 Noven Pharma Forbedret lægemiddeltilførsel i transdermale systemer
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
NZ570295A (en) * 2001-12-05 2011-05-27 Teva Womens Health Inc 28 day oral contraceptive regime package
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CN1863716B (zh) * 2003-09-04 2010-10-27 药品设计有限公司 带有药片接收盘以存放和分配药片的盒子
CN1863537A (zh) * 2003-10-01 2006-11-15 詹森药业有限公司 延长的三阶段避孕法
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2556459C (en) * 2004-03-19 2013-01-15 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
CA2582530A1 (en) * 2004-10-07 2006-04-20 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
CA2640432A1 (en) * 2006-01-27 2007-08-09 Duramed Pharmaceuticals, Inc. Regimens for treatment of conditions related to estrogen deficiency
ES2558030T3 (es) * 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
AT12800U1 (de) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz
WO2010033188A2 (en) * 2008-09-16 2010-03-25 Playtex Products, Llc. Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
EP3297634A1 (en) * 2015-05-18 2018-03-28 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
CA3234836A1 (en) * 2021-09-07 2023-03-16 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4962098A (en) 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
NZ570295A (en) 2001-12-05 2011-05-27 Teva Womens Health Inc 28 day oral contraceptive regime package
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20040251301A1 (en) 2003-05-05 2004-12-16 Niemann Amy C. Device for calculating anticipated days for menstruation
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
CA2771944A1 (en) 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CN1863716B (zh) 2003-09-04 2010-10-27 药品设计有限公司 带有药片接收盘以存放和分配药片的盒子
CN1863537A (zh) 2003-10-01 2006-11-15 詹森药业有限公司 延长的三阶段避孕法

Also Published As

Publication number Publication date
EP0911029A3 (en) 2000-03-29
JPH1129481A (ja) 1999-02-02
DE69804918T2 (de) 2002-11-07
USRE39861E1 (en) 2007-09-25
NO982815D0 (no) 1998-06-18
CA2256977C (en) 2008-11-25
DK0911029T3 (da) 2002-06-17
EP0911029A2 (en) 1999-04-28
DE69804918D1 (de) 2002-05-23
ATE216241T1 (de) 2002-05-15
EP0911029B1 (en) 2002-04-17
ES2175650T3 (es) 2002-11-16
CA2256977A1 (en) 2000-06-23
PT911029E (pt) 2002-09-30
US5898032A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
NO982815L (no) Ultralav dose orale preventiver med mindre menstrasjonsbl°dning og vedvarende virkningsfullhet
ES2033850T3 (es) Forma farmaceutica consistente en una combinacion dosificada, destinada al tratamiento de las mujeres pre-menopausicas.
LU91065I2 (fr) Drospirenone en combinaison avec oestradiol et leurs dérivés pharmaceutiquement acceptables (Allurene-Angeliq)
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
HRP20070188B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
FI103951B1 (fi) Ehkäisyjärjestelmä
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
DK0917466T3 (da) Oralt antikonceptionsmiddel
Olsson Vaginal rings for contraception: endocrine parameters
IT1243978B (it) Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva, nei tumori del seno, dell'utero e nel melanoma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application